Senti Biosciences, Inc. (NASDAQ:SNTI) Sees Significant Increase in Short Interest

Senti Biosciences, Inc. (NASDAQ:SNTI) was the target of a significant growth in short interest in the month of December. As of December 15th, there was short interest totaling 1,663,760 shares, a growth of 458.4% from the November 30th total of 297,970 shares. Currently, 6.5% of the company’s stock are sold short. Based on an average daily volume of 7,431,668 shares, the days-to-cover ratio is presently 0.2 days. Based on an average daily volume of 7,431,668 shares, the days-to-cover ratio is presently 0.2 days. Currently, 6.5% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on SNTI shares. HC Wainwright initiated coverage on shares of Senti Biosciences in a report on Tuesday, October 14th. They issued a “buy” rating and a $12.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Senti Biosciences in a research report on Wednesday, October 8th. Leerink Partnrs raised Senti Biosciences to a “strong-buy” rating in a report on Friday, November 21st. Chardan Capital raised their price objective on Senti Biosciences from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Finally, Leerink Partners assumed coverage on Senti Biosciences in a report on Friday, November 21st. They set an “outperform” rating and a $6.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $9.00.

Senti Biosciences Stock Down 6.5%

NASDAQ:SNTI traded down $0.08 during trading hours on Friday, reaching $1.08. 485,222 shares of the stock were exchanged, compared to its average volume of 526,550. The stock has a market capitalization of $28.26 million, a P/E ratio of -0.32 and a beta of 2.08. The firm has a 50 day simple moving average of $1.81 and a 200-day simple moving average of $1.82. Senti Biosciences has a 52 week low of $1.06 and a 52 week high of $5.10.

Senti Biosciences (NASDAQ:SNTI) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.10). As a group, analysts expect that Senti Biosciences will post -14.54 earnings per share for the current year.

Institutional Investors Weigh In On Senti Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of SNTI. Citadel Advisors LLC acquired a new position in shares of Senti Biosciences during the 3rd quarter valued at $117,000. Armistice Capital LLC bought a new position in Senti Biosciences during the second quarter valued at about $1,883,000. Geode Capital Management LLC grew its holdings in Senti Biosciences by 395.6% during the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after acquiring an additional 117,588 shares during the period. Nantahala Capital Management LLC bought a new stake in Senti Biosciences in the first quarter worth about $2,984,000. Finally, Heights Capital Management Inc. acquired a new stake in Senti Biosciences in the 1st quarter valued at about $2,520,000. Institutional investors and hedge funds own 25.70% of the company’s stock.

Senti Biosciences Company Profile

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.